6-phenyl-1H-pyrazolo[4,3-c]cinnolin-3-ol | 663884-13-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 6-phenyl-1H-pyrazolo[4,3-c]cinnolin-3-ol
• 英文别名: 6-Phenyl-1,2-dihydropyrazolo[4,3-c]cinnolin-3-one
• CAS: 663884-13-7
• 化学式: C₁₅H₁₀N₄O
• 分子量: 262.271
• InChiKey: BXSIGZOIUNDEST-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  20
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  66.9
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  6-bromo-1H-pyrazolo[4,3-c]cinnolin-3-ol 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride sodium carbonate 、 苯硼酸 作用下， 以 1,4-二氧六环 、 乙醇 、 水 为溶剂， 反应 3.0h， 生成 6-phenyl-1H-pyrazolo[4,3-c]cinnolin-3-ol
  参考文献：
  名称：

  [EN] PYRAZOLO (4,3c) CINNOLINE COMPOUNDS AS INHIBITORS OF ITK KINASE ACTIVITY
  [FR] COMPOSES DE PYRAZOLO (4,3C) CINNOLINE COMME INHIBITEURS DE L'ACTIVITE DE LA KINASE ITK

  摘要：

  提供了式（I）的新化合物，其中R和X如规范中所定义，并且其光学异构体、消旋体和互变异构体，以及其药用盐；还提供了它们的制备方法、含有它们的组合物以及它们在治疗中的用途。这些化合物是激酶Itk的抑制剂。

  公开号：

  WO2004016615A1

文献信息

• EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES FROM LIQUID TUMORS AND THERAPEUTIC USES THEREOF
  申请人：Iovance Biotherapeutics, Inc.

  公开号：US20200224161A1

  公开（公告）日：2020-07-16

  Methods of expanding tumor infiltrating lymphocytes (TILs), including peripheral blood lymphocytes and marrow infiltrating lymphocytes, from blood and/or bone marrow of patients with hematological malignancies, such as liquid tumors, including lymphomas and leukemias, and uses of such expanded TILs in the treatment of diseases such as cancers and hematological malignancies are disclosed herein.
• Expansion Of Peripheral Blood Lymphocytes (PBLS) From Peripheral Blood
  申请人：Iovance Biotherapeutics, Inc.

  公开号：US20200347350A1

  公开（公告）日：2020-11-05

  Methods of expanding tumor infiltrating lymphocytes (TILs), including peripheral blood lymphocytes (PBLs) and marrow infiltrating lymphocytes (MILs), from blood and/or bone marrow of patients with hematological malignancies, such as liquid tumors, including lymphomas and leukemias, and genetic modifications of expanded TILs, PBLs, and MILs to incorporate chimeric antigen receptors, genetically modified T-cell receptors, and other genetic modifications, and uses of such expanded and/or modified TILs, PBLs, and MILs in the treatment of diseases such as cancers and hematological malignancies are disclosed herein.
• PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY
  申请人：Iovance Biotherapeutics, Inc.

  公开号：US20220118011A1

  公开（公告）日：2022-04-21

  The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. Such TILs find use in therapeutic treatment regimens.
• Expansion of Tumor Infiltrating Lymphocytes From Liquid Tumors and Therapeutic Uses Thereof
  申请人：Iovance Biotherapeutics, Inc.

  公开号：US20220133795A1

  公开（公告）日：2022-05-05

  Methods of expanding peripheral blood lymphocytes (PBLs) from blood of patients with hematological malignancies, including lymphomas and leukemias, genetic modifications of expanded PBLs to incorporate chimeric antigen receptors, genetically modified T cell receptors, and other genetic modifications, and uses of such expanded and/or modified PBLs in the treatment of diseases such as cancers and hematological malignancies are disclosed herein.
• [EN] USE OF Itk INHIBITORS FOR THE TREATMENT OF MAST CELL-DRIVEN OR BASOPHIL-DRIVEN DISEASES<br/>[FR] UTILISATION D'INHIBITEURS DE L'ITK POUR LE TRAITEMENT DE MALADIES INDUITES PAR LES MASTOCYTES OU PAR LES BASOPHILES
  申请人：ASTRAZENECA AB

  公开号：WO2004016270A1

  公开（公告）日：2004-02-26

  The present invention relates to the treatment of mast cell-driven or basophil-driven conditions or diseases by inhibiting the activity of Inducible T cell kinase (Itk). Particular conditions or diseases that may be treated include asthma, rhinitis, COPD.